4
Clinical Trials associated with Liraglutide(Aulbio)An open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,cross-over, bioequivalence study of Liraglutide 0.6 mg Injection (6 mg/mL) (Test) of VirchowBiotech Private Limited, India and Victoza® (Liraglutide) injection in pre-filled pen 0.6 mg (6 mg/mL) of Novo Nordisk A/S Novo Allé DK-2880 Bagsværd, Denmark in normal, healthy adult,human subjects under fasting conditions. - Nil
An open label, balanced, randomized, two treatment, two period, two-way crossover study to compare the single & multiple dose (steady state) pharmacokinetics profile of Biosimilar Liraglutide injection with Victoza® in healthy adult, human subjects.
Comparison of the efficacy of insulin degludec/insulin aspart and insulin degludec/liraglutide in patients with type 2 diabetes - Comparison of the efficacy of insulin degludec/insulin aspart and insulin degludec/liraglutide in patients with type 2 diabetes
Start Date10 Feb 2020 |
Sponsor / Collaborator- |
100 Clinical Results associated with Liraglutide(Aulbio)
100 Translational Medicine associated with Liraglutide(Aulbio)
100 Patents (Medical) associated with Liraglutide(Aulbio)
100 Deals associated with Liraglutide(Aulbio)